Fig. 2From: Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s diseaseTitration schedule for transdermal patches of rivastigmine or placeboBack to article page